• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.更正：维莫德吉治疗晚期基底细胞癌患者的长期安全性和疗效：关键ERIVANCE BCC研究的最终更新。
BMC Cancer. 2019 Apr 18;19(1):366. doi: 10.1186/s12885-019-5568-6.
2
Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.Erivance 关键性基底细胞癌（BCC）研究：维莫德吉治疗晚期 BCC 的疗效和安全性 12 个月更新。
J Am Acad Dermatol. 2015 Jun;72(6):1021-6.e8. doi: 10.1016/j.jaad.2015.03.021.
3
Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.维莫德吉治疗基底细胞癌：ERIVANCE BCC试验的结果及意义
Future Oncol. 2014 May;10(6):927-36. doi: 10.2217/fon.14.50.
4
Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.维莫德吉治疗基底细胞痣综合征患者的安全性和有效性：两项试验的汇总分析
Orphanet J Rare Dis. 2016 Sep 1;11(1):120. doi: 10.1186/s13023-016-0506-z.
5
Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.维莫德吉在≥65岁晚期基底细胞癌患者中的安全性和有效性。
Oncotarget. 2016 Nov 15;7(46):76118-76124. doi: 10.18632/oncotarget.12660.
6
A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.对刺猬信号通路及维莫德吉在基底细胞癌治疗中作用的全面综述。
Curr Med Res Opin. 2015 Apr;31(4):743-56. doi: 10.1185/03007995.2015.1018988. Epub 2015 Mar 17.
7
Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.晚期基底细胞癌患者接受 Hedgehog 通路抑制剂维莫德吉治疗的扩大准入研究。
J Am Acad Dermatol. 2014 Jan;70(1):60-9. doi: 10.1016/j.jaad.2013.09.012. Epub 2013 Nov 1.
8
Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma.维莫德吉在晚期眼周基底细胞癌治疗中的作用
Cancer Control. 2016 Apr;23(2):133-9. doi: 10.1177/107327481602300207.
9
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.维莫德吉治疗晚期基底细胞癌患者：国际开放标签试验STEVIE的初步分析
Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5.
10
Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.维莫德吉治疗基底细胞癌后皮肤鳞状细胞癌风险增加。
JAMA Dermatol. 2016 May 1;152(5):527-32. doi: 10.1001/jamadermatol.2015.4330.

引用本文的文献

1
Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.局部晚期和转移性基底细胞癌的 Hedgehog 通路抑制剂：真实世界的单中心回顾性研究。
PLoS One. 2024 Apr 30;19(4):e0297531. doi: 10.1371/journal.pone.0297531. eCollection 2024.
2
New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.新兴治疗选择用于晚期基底细胞癌和鳞状细胞癌。
Adv Ther. 2022 Mar;39(3):1164-1178. doi: 10.1007/s12325-022-02044-1. Epub 2022 Jan 28.
3
SKIN-COBRA (Consortium for Brachytherapy data Analysis) ontology: The first step towards interdisciplinary standardized data collection for personalized oncology in skin cancer.皮肤癌近距离放射治疗数据分析联盟（SKIN-COBRA）本体论：迈向皮肤癌个性化肿瘤学跨学科标准化数据收集的第一步。
J Contemp Brachytherapy. 2020 Apr;12(2):105-110. doi: 10.5114/jcb.2020.94579. Epub 2020 Apr 30.
4
Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.Sonic Hedgehog 通路抑制在晚期基底细胞癌治疗中的应用。
Curr Treat Options Oncol. 2019 Nov 26;20(11):84. doi: 10.1007/s11864-019-0683-9.

本文引用的文献

1
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.维莫德吉治疗晚期基底细胞癌患者的长期安全性和有效性：关键ERIVANCE BCC研究的最终更新
BMC Cancer. 2017 May 16;17(1):332. doi: 10.1186/s12885-017-3286-5.

更正：维莫德吉治疗晚期基底细胞癌患者的长期安全性和疗效：关键ERIVANCE BCC研究的最终更新。

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

作者信息

Sekulic Aleksandar, Migden Michael R, Basset-Seguin Nicole, Garbe Claus, Gesierich Anja, Lao Christopher D, Miller Chris, Mortier Laurent, Murrell Dedee F, Hamid Omid, Quevedo Jorge F, Hou Jeannie, McKenna Edward, Dimier Natalie, Williams Sarah, Schadendorf Dirk, Hauschild Axel

机构信息

Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA.

Departments of Dermatology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA.

出版信息

BMC Cancer. 2019 Apr 18;19(1):366. doi: 10.1186/s12885-019-5568-6.

DOI:10.1186/s12885-019-5568-6
PMID:30999949
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6474043/
Abstract

Following publication of the original article [1], it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is.

摘要

在原文章[1]发表之后，有报道称图1的图例不完整。完整的图例如下。